RecruitingEarly Phase 1NCT06122896

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Sponsor

Dana-Farber Cancer Institute

Enrollment

5,000 participants

Start Date

Nov 21, 2023

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Neoplasm

Summary

The purpose of this research is to see if adding blood-based tests and symptom review to standard-of-care pancreatic cancer screening procedures can identify cancer early among individuals with increased risk.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial screens people with inherited gene changes or strong family histories for early signs of pancreatic cancer, aiming to catch it at a stage when it is most treatable. **You may be eligible if...** - You carry a gene mutation linked to pancreatic cancer risk (such as STK11, CDKN2A, ATM, BRCA1, BRCA2, PALB2, or others) and meet the age requirements for each gene - You have a strong family history of pancreatic cancer (two or more first-degree relatives on the same side of the family) - You have hereditary pancreatitis caused by PRSS1 gene changes **You may NOT be eligible if...** - You have already been diagnosed with pancreatic cancer - You do not meet the specific age and genetic criteria for your risk category Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERScreening Blood Tests

Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.

DIAGNOSTIC_TESTEndoscopic Ultrasound

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCTMagnetic Resonance Imaging

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

COMBINATION_PRODUCTMagnetic Resonance Cholangiopancreatography

Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.

Locations(2)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06122896

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121279 locations

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT0630524712 locations

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0725223217 locations